Novo Nordisk is withdrawing Victoza from the UK and EU by end of 2026, making generic liraglutide the supply route buyers in those markets now need.
Victoza, the original liraglutide brand for type 2 diabetes, is being withdrawn from the UK and EU by Novo Nordisk on commercial grounds, with UK supply gone since 2023 and full EU exit due by the end of 2026. Saxenda, the liraglutide brand for weight management, is unaffected. As the originator exits, generic liraglutide entering the market since the 2023 patent expiry is what keeps regulatory teams, procurement and tender desks able to maintain continuity. M Care Exports sources liraglutide from WHO-GMP certified Indian manufacturers to your registered specification.
Liraglutide exporter and bulk supplier from India.
Liraglutide ships as a cold-chain product: pre-filled pens require continuous refrigerated transport from despatch to the importer's own storage, protected from light and never frozen, with the permitted in-use, room-temperature window defined on the destination's own approved label rather than assumed from the reference product. Export documentation is built around a Certificate of Analysis and Certificate of Pharmaceutical Product referencing the manufacturer's own marketing authorisation, cold-chain shipment validation and temperature logging for the transit leg, and packing configured to the destination pack size on the buyer's registered dossier. As a non-scheduled, WHO-GMP sourced injectable, liraglutide carries no controlled-substance export licensing beyond CDSCO's standard export documentation for a temperature-sensitive product.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist), sourced and documented for export.
Novo Nordisk is discontinuing the Victoza brand of liraglutide across the UK and EU by the end of 2026, a commercial withdrawal, not a safety recall, that leaves buyers in those exact markets needing a generic supply route as the patent estate cleared in 2023. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, formulated as a 6 mg/mL solution for subcutaneous injection delivered through a pre-filled, dose-adjustable pen. It carries the class's thyroid C-cell tumor signal seen in rodent studies, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The same 6 mg/mL formulation is marketed separately as Saxenda for chronic weight management at a higher titrated dose, a brand Novo Nordisk has confirmed it is not discontinuing. M Care supplies generic liraglutide to the destination's own registered label.
Active ingredient
Liraglutide. GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist).
Forms and strengths
6 mg/mL.
Indications
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated as a 6 mg/mL solution for subcutaneous injection, marketed under separate brand registrations for type 2 diabetes management and, at a higher titrated dose, for chronic weight management.
Administration
Subcutaneous injection. Solution for injection (pre-filled, dose-adjustable pen).
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers are regulatory affairs teams and hospital or retail pharmacy procurement in the UK and EU managing formulary continuity as Victoza exits, tender desks in Gulf and GCC markets running diabetes and endocrine lot procurement, and licensed importers in Africa, Latin America, Southeast Asia and CIS sourcing generic liraglutide for registration in their own territory. Buyers typically already hold, or are in the process of obtaining, an import or wholesale distribution licence for their jurisdiction; M Care does not sell into markets without one. Enquiries most often come from procurement teams replacing a Victoza line already on their formulary, and from importers filing a new generic liraglutide registration behind the 2023 patent expiry.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on liraglutide.
A pharmacist reviewing a liraglutide line checks that the product is the 6 mg/mL solution formulation, since this is the only marketed strength: the difference between the diabetes indication (up to 1.8 mg once daily) and the weight-management indication (titrated to 3.0 mg once daily) is a dosing decision made via the pen's dial, not a separate strength. Cold-chain integrity across the shipment is the first quality check, given the peptide's stability profile; a pharmacist verifies unbroken temperature logging rather than accepting a supplier's assurance alone. Because the reference product carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, the destination's approved label and patient information leaflet must carry the equivalent warning, not a stripped-down generic label. For liraglutide sourced against the discontinuing Victoza registration specifically, a pharmacist also confirms the buyer's own regulator has published discontinuation or shortage guidance for Victoza, since both MHRA and EMA have issued communications directing prescribers to alternative therapies as Novo Nordisk exits.
The documentation pack a regulator actually asks for.
The documentation pack for a liraglutide line includes the manufacturer's own marketing authorisation or equivalent approval in its country of manufacture, WHO-GMP certification for the manufacturing site, a Certificate of Analysis per batch, a Certificate of Pharmaceutical Product where the destination regulator requires one, and stability data supporting the cold-chain claim on the label. M Care Exports itself holds ISO 9001:2015 certification and a CDSCO export licence; it is a merchant-exporter and does not manufacture, and does not hold WHO-GMP or WHO-PQ certification in its own name. Because the Victoza originator registration is being withdrawn in the UK and EU on the manufacturer's own commercial timetable, buyers replacing that line with a generic should expect their own regulator to require a fresh or bridged marketing authorisation review rather than a straightforward substitution, and should confirm registration status with their national authority before committing tender volumes. All batch documentation is issued against the buyer's own registered specification, with availability of a specific line confirmed at enquiry.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
Boxed warning: risk of thyroid C-cell tumors observed in rodent studies; human relevance not established
Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Contraindicated in patients with a prior serious hypersensitivity reaction to liraglutide or any product component
Not a controlled substance; not scheduled for export licensing purposes
Victoza brand undergoing phased commercial withdrawal from the UK and EU, complete by end of 2026 (not a safety recall); UK supply has been unavailable since 2023; Saxenda brand unaffected
Requires continuous cold-chain transport (refrigerated, protected from light, do not freeze), with the in-use room-temperature window defined on the destination's own approved label
Adjacent lines procurement desks order alongside liraglutide.
Dapagliflozin metformin
Another diabetes & endocrine line ordered on the same formularies.
Gliclazide
Another diabetes & endocrine line ordered on the same formularies.
Glimepiride
Another diabetes & endocrine line ordered on the same formularies.
All diabetes & endocrine
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for liraglutide.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Liraglutide supply, the specific questions.
Why is Victoza being withdrawn from the UK and EU?
Novo Nordisk has confirmed the withdrawal is a commercial portfolio decision, not a response to a safety or quality issue with the product. UK supply ended in 2023, and the company has stated it will complete the exit across all EU/EEA member states by the end of 2026, coordinating transition guidance with EMA and national regulators as it does.
Is Saxenda affected by the same withdrawal?
No. Novo Nordisk has stated it has no plans to discontinue Saxenda, the liraglutide brand approved for chronic weight management. Saxenda uses the same 6 mg/mL formulation as Victoza but is titrated to a higher maximum dose and sold under a separate registration for a separate indication.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care Exports is a merchant-exporter, not a manufacturer, and holds ISO 9001:2015 certification and a CDSCO export licence in its own name. Liraglutide supplied through M Care is sourced from WHO-GMP certified Indian manufacturers, with that certification held at the manufacturing site, not by M Care itself.
What is the main safety warning attached to liraglutide?
Liraglutide carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies where the human relevance has not been established. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and buyers should confirm the destination label carries the equivalent warning.
Can generic liraglutide replace a Victoza line on an existing tender?
Patent protection on liraglutide's active ingredient cleared in the US and EU in 2023, and generic approvals followed from 2024 onward. Whether a specific generic can substitute for a Victoza-referenced tender line depends on the buyer's own regulator and the terms of the original award, which the buyer's regulatory team should confirm.
What strength and presentation does M Care supply liraglutide in?
Liraglutide is marketed as a 6 mg/mL solution for subcutaneous injection in a pre-filled, dose-adjustable pen. This is the only strength in which the molecule is marketed; the diabetes and weight-management doses are reached by adjusting the pen, not by using a different-strength product.
What documentation does M Care provide with a liraglutide shipment?
Shipments are documented with a Certificate of Analysis per batch, the manufacturer's own marketing authorisation or equivalent approval, and a Certificate of Pharmaceutical Product where the destination regulator requires one, along with cold-chain shipment and temperature-logging records for the transit leg.
Is liraglutide a controlled substance for export purposes?
No. Liraglutide is not scheduled as a controlled substance. Export documentation is built around standard CDSCO requirements for a temperature-sensitive injectable, not controlled-drug export licensing.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.